Aurobindo Pharma arm gets 3 USFDA observations for AP injectable facility

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-04-07 07:30 GMT   |   Update On 2024-04-07 07:30 GMT

Hyderabad: In a recent BSE filing, Aurobindo Pharma has informed that the new injectable facility of Eugia Steriles Private Limited, a 100% subsidiary of Eugia Pharma Specialities Limited and a stepdown subsidiary of the Company, situated at Parawada Mandal, Anakapalli District, Andhra Pradesh, has recently started the commercial operations. The United States Food and Drug Administration...

Login or Register to read the full article

Hyderabad: In a recent BSE filing, Aurobindo Pharma has informed that the new injectable facility of Eugia Steriles Private Limited, a 100% subsidiary of Eugia Pharma Specialities Limited and a stepdown subsidiary of the Company, situated at Parawada Mandal, Anakapalli District, Andhra Pradesh, has recently started the commercial operations.

The United States Food and Drug Administration (US FDA) inspected the above-mentioned facility from March 28, 2024 to April 05, 2024.

The inspection closed with 3 observations.

"The observations are procedural in nature and will be responded to within the stipulated time," the Company stated.

Read also: Aurobindo Pharma bags USFDA nod for Mometasone Furoate Monohydrate Nasal Spray

Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 25 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company’s product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, AntiRetroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

Read also: Aurobindo Pharma arm announces successful Phase 1 clinical study outcome of their BP11 product

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News